This clinical trial is focused on studying the effects of a medication called Upadacitinib on a condition known as Axial Spondyloarthritis. Axial Spondyloarthritis is a type of arthritis that primarily affects the spine and the joints connecting the spine to the pelvis, causing pain and stiffness. The study aims to evaluate how well Upadacitinib works in reducing the signs and symptoms of this condition and to assess its safety for patients.

Participants in the study will receive either Upadacitinib or a placebo, which is a substance with no active medication. The study is designed to be “double-blind,” meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo. This helps ensure that the results are not influenced by expectations about the treatment. The study will also include a period where participants who respond well to the treatment will have their medication gradually withdrawn to observe if they can maintain remission, which is a state where symptoms are reduced or disappear.

The trial will be conducted over several weeks, with regular check-ups to monitor the participants’ health and the effects of the medication. The primary goal is to see if Upadacitinib can significantly improve the condition of patients with Axial Spondyloarthritis compared to those who receive the placebo. Participants will be closely monitored for any side effects or changes in their condition throughout the study period.